Mitotech published the results of its Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome Advances in Therapy journal. This open access publication can be found here:
About Mitotech S.A Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed antioxidants. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.